GlassScriptPhysician profile
Belin Fred Bodie
NPI 1891798807
$1,800.82
in general payments reported to CMS, 2019-2025
21 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $73.53 · 2021: $318 · 2022: $363 · 2023: $96.57 · 2024: $183 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.25 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill Dermaceuticals, INC. | $320.32 | 2022-2024 | Tolak |
| Janssen Biotech, INC. | $317.10 | 2019-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $231.80 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $181.03 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $119.01 | 2019 | |
| Paratek Pharmaceuticals, INC. | $86.83 | 2025 | Nuzyra |
| Lilly USA, LLC | $60.33 | 2020-2021 | |
| Hologic Sales and Service, LLC | $41.35 | 2024-2025 | Fluent Fluid Management System, Myosure Tissue Removal Device, Novasure |
| Cipher Pharmaceuticals US LLC | $37.45 | 2025 | Spinosad, Natroba |
| Almirall LLC | $36.73 | 2023-2025 | Seysara |
| Dermavant Sciences, INC. | $35.34 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.73 | 2022-2024 | Spevigo |
| Amgen INC. | $30.93 | 2023 | Otezla |
| Genzyme Corporation | $30.64 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $30.28 | 2019-2021 | |
| Organon LLC | $28.22 | 2025 | Vtama |
| Abbvie INC. | $21.43 | 2024 | |
| Hartmann USA, INC. | $17.50 | 2025 | Zetuvit Plus 10x10 P10 |
| Ucb, INC. | $15.80 | 2025 | Bimzelx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Belin Bodie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.